GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX (cannabidiol) Oral Solution to Schedule V
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering
